What is the primary treatment option for patients with rheumatoid arthritis?

The primary treatment option for patients with rheumatoid arthritis is the use of disease-modifying antirheumatic drugs (DMARDs). These medications are specifically designed to slow the progression of the disease and prevent joint damage, which is a critical aspect of managing rheumatoid arthritis. DMARDs work by modifying the underlying immune response that contributes to inflammation and joint destruction, ultimately improving long-term outcomes for patients.

By starting DMARDs early in the treatment process, healthcare providers aim to achieve remission or low disease activity, which can significantly enhance the quality of life for those affected by rheumatoid arthritis. Some common examples of DMARDs include methotrexate, sulfasalazine, and leflunomide.

The other treatment options listed are either supportive care measures or aimed at symptom management rather than addressing the disease process itself. Pain relievers and antibiotics may help manage pain and treat infections, but they do not halt the progression of rheumatoid arthritis. Massage therapy and supplements might provide relief or supportive benefits but lack the scientific foundation to be considered primary treatment. Corticosteroids can reduce inflammation in the short term, and physical therapy is beneficial for maintaining joint function, but neither serves as a primary disease-modifying treatment like DMARDs do.